InsiderTrades.com logo
Michael Kaseta net worth and biography
  • LinkedIn
  • Phone
  • Email
  • Website

Michael Kaseta Biography and Net Worth

CFO of Liquidia

Michael Kaseta joined Liquidia in 2020 where he serves as Chief Operating Officer and Chief Financial Officer. His extensive background spans corporate finance, business strategy and the commercialization of biopharma products in large pharmaceutical companies and small biotech companies. Prior to Liquidia, Michael served as the Chief Financial Officer at Aerami Therapeutics, a private biotech company focused on the development of improved therapies for the treatment of severe respiratory diseases, including pulmonary arterial hypertension (PAH). Previously, he served as the Chief Financial Officer at Aralez Pharmaceuticals Inc. (Nasdaq: ARLZ) and spent 11 years at Sanofi in a variety of financial roles, culminating in the Chief Financial Officer at Sanofi SA for North America Global Services and the North America Pharmaceutical Region. In this role he managed a $10 billion business covering several product launches and more than 100 products across eight therapeutic areas. Michael holds a Bachelor of Business Administration in accounting from James Madison University, is a Certified Public Accountant (inactive) licensed in the state of New Jersey and serves on the Board of Directors at Heron Therapeutics and Bryn Pharma.

What is Michael Kaseta's net worth?

The estimated net worth of Michael Kaseta is at least $6.27 million as of January 14th, 2025. Kaseta owns 401,755 shares of Liquidia stock worth more than $6,267,378 as of March 26th. This net worth estimate does not reflect any other assets that Kaseta may own. Additionally, Kaseta receives a salary of $890,800.00 as CFO at Liquidia. Learn More about Michael Kaseta's net worth.

How old is Michael Kaseta?

Kaseta is currently 48 years old. There are 5 older executives and no younger executives at Liquidia. The oldest executive at Liquidia is Dr. Roger A. Jeffs Ph.D., CEO & Director, who is 62 years old. Learn More on Michael Kaseta's age.

What is Michael Kaseta's salary?

As the CFO of Liquidia Co., Kaseta earns $890,800.00 per year. The highest earning executive at Liquidia is Dr. Roger A. Jeffs Ph.D., CEO & Director, who commands a salary of $1,320,000.00 per year. Learn More on Michael Kaseta's salary.

How do I contact Michael Kaseta?

The corporate mailing address for Kaseta and other Liquidia executives is 419 DAVIS DRIVE SUITE 100, MORRISVILLE NC, 27560. Liquidia can also be reached via phone at (919) 328-4400 and via email at ir@liquidia.com. Learn More on Michael Kaseta's contact information.

Has Michael Kaseta been buying or selling shares of Liquidia?

During the last quarter, Michael Kaseta has sold $275,298.60 in Liquidia stock. Most recently, Michael Kaseta sold 23,370 shares of the business's stock in a transaction on Tuesday, January 14th. The shares were sold at an average price of $11.78, for a transaction totalling $275,298.60. Following the completion of the sale, the chief financial officer now directly owns 401,755 shares of the company's stock, valued at $4,732,673.90. Learn More on Michael Kaseta's trading history.

Who are Liquidia's active insiders?

Liquidia's insider roster includes Jason Adair (Chief Business Officer), Roger Jeffs (CEO), Michael Kaseta (CFO), Arthur Kirsch (Director), Paul Manning (Director), Scott Moomaw (Chief Commercial Officer), Rajeev Saggar (Insider), and Russell Schundler (General Counsel). Learn More on Liquidia's active insiders.

Are insiders buying or selling shares of Liquidia?

In the last year, Liquidia insiders bought shares 1 times. They purchased a total of 150,000 shares worth more than $1,426,500.00. In the last year, insiders at the sold shares 31 times. They sold a total of 133,327 shares worth more than $1,616,512.79. The most recent insider tranaction occured on January, 27th when insider Jason Adair sold 445 shares worth more than $6,319.00. Insiders at Liquidia own 30.1% of the company. Learn More about insider trades at Liquidia.

Information on this page was last updated on 1/27/2025.

Michael Kaseta Insider Trading History at Liquidia

See Full Table

Michael Kaseta Buying and Selling Activity at Liquidia

This chart shows Michael Kaseta's buying and selling at Liquidia by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$275ksoldQ1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1-$200k-$100k$0$100k$200kTotal Insider BuyingTotal Insider Selling

Liquidia Company Overview

Liquidia logo
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company also offers Remodulin, a treprostinil administered through continuous intravenous and subcutaneous infusion. The company also a license agreement with Pharmosa Biopharm Inc to develop and commercialize L606, an inhaled sustained-release formulation of Treprostinil for the treatment of PAH and PH-ILD. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.
Read More

Today's Range

Now: $15.60
Low: $15.47
High: $15.77

50 Day Range

MA: $14.95
Low: $12.14
High: $16.52

2 Week Range

Now: $15.60
Low: $8.26
High: $16.81

Volume

676,229 shs

Average Volume

931,979 shs

Market Capitalization

$1.33 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.07